Jiangsu Hengrui Medicine's (SHA:600276, HKG:1276) unit, Shandong Shengdi Pharmaceutical, received approval from China's National Medical Products Administration to conduct clinical trials on HRS-1780 tablets, according to a Shanghai bourse disclosure on Saturday.
The pharmaceutical company's Shanghai shares fell 2% and Hong Kong shares slipped less than 1% during Monday's midday trade.
The drug will be tested as a treatment for adult patients with heart failure with a left ventricular ejection fraction of more than 40%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments